

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 27, No 19

C O N T E N T S

July 1, 2009

Editorials

Phase II Trials in *Journal of Clinical Oncology*

Stephen A. Cannistra 3073

ATR Mutations in Endometrial Cancer: A Window Into the Role of Mismatch Repair Defects

Noah D. Kauff (see article on page 3091) 3077

Epothilones: Better or More of the Same?

Paul Sabbatini and David R. Spriggs (see articles on pages 3097 and 3104) 3079

Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In

Michael J. O'Connell (see articles on pages 3109 and 3117) 3082

Soft Tissue Sarcoma Trials: One Size No Longer Fits All

Jaap Verweij (see articles on pages 3126, 3133, 3141, 3148, and 3154) 3085

Epigenetic Events Highlight the Challenge of Validating Prognostic Biomarkers During the Clinical and Biologic Evolution of Prostate Cancer

Phillip G. Febbo (see article on page 3161) 3088

Original Reports

GYNECOLOGIC CANCER

④ ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes

Israel Zigelboim, Amy P. Schmidt, Feng Gao, Premal H. Thaker, Matthew A. Powell, Janet S. Rader, Randall K. Gibb, David G. Mutch, and Paul J. Goodfellow (see editorial on page 3077) 3091

④ Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study

Wim W. ten Bokkel Huinink, Jozef Sufliarsky, Willem M. Smit, Stanislav Spanik, Maria Wagnerova, Hal W. Hirte, Stan Kaye, Anandhi R. Johri, and Amit M. Oza (see editorial on page 3079 and article on page 3104) 3097

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 2318 Mill Road, Suite 800, Alexandria, VA 22314.

2009 annual subscription rates, effective September 1, 2008: United States and possessions: individual, \$556; single issue, \$40. International: individual, \$772; single issue, \$50. Institutions: Tier 1: \$786 US, \$1,086 Int'l; Tier 2: \$915 US, \$1,214 Int'l; Tier 3: \$1,321 US, \$1,610 Int'l; Tier 4: \$1,455 US, \$1,744 Int'l; Tier 5: contact JCO for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$278; all other countries, \$386. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

① Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P Don S. Dizon, John A. Blessing, D. Scott McMeekin, Sudarshan K. Sharma, Paul DiSilvestro, and Ronald D. Alvarez (see editorial on page 3079 and article on page 3097)	3104
---	------

GASTROINTESTINAL CANCER

① Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial Thierry André, Corrado Boni, Matilde Navarro, Josep Tabernero, Tamas Hickish, Clare Topham, Andrea Bonetti, Philip Clingan, John Bridgewater, Fernando Rivera, and Aimery de Gramont (see editorial on page 3082 and article on page 3117)	3109
---	------

① Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3 Eric Van Cutsem, Roberto Labianca, György Bodoky, Carlo Barone, Enrique Aranda, Bernard Nordlinger, Claire Topham, Josep Tabernero, Thierry André, Alberto F. Sobrero, Enrico Mini, Richard Greil, Francesco Di Costanzo, Laurence Collette, Laura Cisar, Xiaoxi Zhang, David Khayat, Carsten Bokemeyer, Arnaud D. Roth, and David Cunningham (see editorial on page 3082 and article on page 3109)	3117
---	------

SARCOMAS

① Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Stefan Sleijfer, Isabelle Ray-Coquard, Zsuzsa Papp, Axel Le Cesne, Michelle Scurr, Patrick Schöffski, Françoise Collin, Lini Pandite, Sandrine Marreaud, Annick De Brauwer, Martine van Glabbeke, Jaap Verweij, and Jean-Yves Blay (see editorial on page 3085 and articles on pages 3133, 3141, 3148, and 3154)	3126
---	------

① Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas Robert G. Maki, David R. D’Adamo, Mary L. Keohan, Michael Saulle, Scott M. Schuetze, Samir D. Undevia, Michael B. Livingston, Matthew M. Cooney, Martee L. Hensley, Monica M. Mita, Chris H. Takimoto, Andrew S. Kraft, Anthony D. Elias, Bruce Brockstein, Nathalie E. Blachère, Mark A. Edgar, Lawrence H. Schwartz, Li-Xuan Qin, Cristina R. Antonescu, and Gary K. Schwartz (see editorial on page 3085 and articles on pages 3126, 3141, 3148, and 3154)	3133
---	------

① Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors George D. Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D. Blanke, Heikki Joensuu, and Margaret von Mehren (see editorial on page 3085 and articles on pages 3126, 3133, 3148, and 3154)	3141
--	------

Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model Rashmi Chugh, J. Kyle Wathen, Robert G. Maki, Robert S. Benjamin, Shreyaskumar R. Patel, Paul A. Myers, Dennis A. Priebe, Denise K. Reinke, Dafydd G. Thomas, Mary L. Keohan, Brian L. Samuels, and Laurence H. Baker (see editorial on page 3085 and articles on pages 3126, 3133, 3141, and 3154)	3148
---	------

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas Suzanne George, Priscilla Merriam, Robert G. Maki, Annick D. Van den Abbeele, Jeffrey T. Yap, Timothy Akhurst, David C. Harmon, Gauri Bhuchar, Margaret M. O’Mara, David R. D’Adamo, Jeffrey Morgan, Gary K. Schwartz, Andrew J. Wagner, James E. Butrynski, George D. Demetri, and Mary L. Keohan (see editorial on page 3085 and articles on pages 3126, 3133, 3141, and 3148)	3154
---	------

GENITOURINARY CANCER

- ① **Promoter Methylation in *APC*, *RUNX3*, and *GSTP1* and Mortality in Prostate Cancer Patients**
Lorenzo Richiardi, Valentina Fiano, Loredana Vizzini, Laura De Marco, Luisa Delsedime, Olof Akre, Anna Gillio Tos, and Franco Merletti (see editorial on page 3088) 3161
- ① **The Effects of a Presurgical Stress Management Intervention for Men With Prostate Cancer Undergoing Radical Prostatectomy**
Patricia A. Parker, Curtis A. Pettaway, Richard J. Babaian, Louis L. Pisters, Brian Miles, Adoneca Fortier, Qi Wei, Danielle D. Carr, and Lorenzo Cohen 3169
- ① **MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02**
Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, Tahseen Al-Saleem, M. Elizabeth Hammond, David J. Grignon, Mingxin Che, Varagur Venkatesan, Roger W. Byhardt, Marvin Rotman, Gerald E. Hanks, Howard M. Sandler, and Alan Pollack 3177

BREAST CANCER

- ① **Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer**
Cornelia Liedtke, Christos Hatzis, William Fraser Symmans, Christine Desmedt, Benjamin Haibe-Kains, Vicente Valero, Henry Kuerer, Gabriel N. Hortobagyi, Martine Piccart-Gebhart, Christos Sotiriou, and Lajos Pusztai 3185
- ① **Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOB0E Trial**
Emanuela Rossi, Alessandro Morabito, Francesca Di Rella, Giuseppe Esposito, Adriano Gravina, Vincenzo Labonia, Gabriella Landi, Francesco Nuzzo, Carmen Pacilio, Ermelinda De Maio, Massimo Di Maio, Maria Carmela Piccirillo, Gianfranco De Feo, Giuseppe D'Aiuto, Gerardo Botti, Paolo Chiodini, Ciro Gallo, Francesco Perrone, and Andrea de Matteis 3192

LEUKEMIA AND BONE MARROW TRANSPLANTATION

- ① **Prognostic Importance of *MN1* Transcript Levels, and Biologic Insights From *MN1*-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study**
Christian Langer, Guido Marcucci, Kelsi B. Holland, Michael D. Radmacher, Kati Maharry, Peter Paschka, Susan P. Whitman, Krzysztof Mrózek, Claudia D. Baldus, Ravi Vij, Bayard L. Powell, Andrew J. Carroll, Jonathan E. Kollitz, Michael A. Caligiuri, Richard A. Larson, and Clara D. Bloomfield 3198

CLINICAL TRIALS

- Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation**
Shauna L. Hillman, Ming-Wen An, Michael J. O'Connell, Richard M. Goldberg, Paul Schaefer, Jan C. Buckner, and Daniel J. Sargent 3205

PALLIATIVE AND SUPPORTIVE CARE

- Adherence to Long-Term Surveillance Mammography Among Women With Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery**
Larissa Nekhlyudov, Laurel A. Habel, Ninah S. Achacoso, Inkyung Jung, Reina Haque, Laura C. Collins, Stuart J. Schnitt, Charles P. Quesenberry Jr, and Suzanne W. Fletcher 3211

THORACIC ONCOLOGY

① Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Bjørn H. Grønberg, Roy M. Bremnes, Øystein Fløtten, Tore Amundsen, Paal Fr. Brunsvig, Harald H. Hjelde, Stein Kaasa, Christian von Plessen, Frøydis Stornes, Terje Tollåli, Finn Wammer, Ulf Aasebø, and Stein Sundstrøm 3217

Review Article

① Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient

Brian I. Rini 3225

ASCO Special Article

① American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Kala Visvanathan, Rowan T. Chlebowski, Patricia Hurley, Nananda F. Col, Mary Ropka, Deborah Collyar, Monica Morrow, Carolyn Runowicz, Kathleen I. Pritchard, Karen Hagerty, Banu Arun, Judy Garber, Victor G. Vogel, James L. Wade, Powel Brown, Jack Cuzick, Barnett S. Kramer, and Scott M. Lippman 3235

Art of Oncology

① “I Think You Are Pretty; I Don’t Know Why Everyone Can’t See That”: Reflections From a Young Adult Brain Tumor Survivor Camp

Deborah B. Crom 3259

e. Diagnosis in Oncology

Sister Mary Joseph’s Nodule As a Diagnostic Clue to Metastatic Colon Carcinoma

Zhu Shen, Xichuan Yang, Ling Chen, Fei Hao, and Baiyu Zhong e1

e. Correspondence

Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study

Ian Chau, Sue Ashley, and David Cunningham e3

Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer

Cecile Badoual, Stephane Hans, Wolf H. Fridman, Daniel Brasnu, Susan Erdman, and Eric Tartour e5

Reply to C. Badoual et al

Paul Salama, Cameron Platell, and Barry Iacopetta e7

Fluorescent In Situ Hybridization for Human Epidermal Growth Factor Receptor 2 Assessment in Breast Cancer: Is It Applicable As a Primary Test?

Vincenzo Arena, Iliaria Pennacchia, Arnaldo Carbone, and Arnaldo Capelli e8

Reply to V. Arena et al

Guido Sauter, James Lee, John M.S. Bartlett, Dennis J. Slamon, and Michael F. Press e9

Cutaneous Melanoma During Pregnancy: Is the Controversy Over?

Marko Lens, Inger Rosdahl, and Julia Newton-Bishop e11

Reply to M. Lens et al

Hanne Stensheim, Bjørn Møller, Tini van Dijk, and Sophie D. Fosså e13

Errata

Ruzzo A, Graziano F, Loupakis F, et al: J Clin Oncol 25:1247-1254, 2007	3262
Kyriakou C, Canals C, Goldstone A, et al: J Clin Oncol 26:218-224, 2008	3262
Huo D, Senie RT, Daly M, et al: J Clin Oncol 27:1184-1190, 2009	3262
Galanis E, Jaeckle KA, Maurer MJ, et al: J Clin Oncol 27:2052-2058, 2009	3262
Thomas MB, Morris JS, Chadha R, et al: J Clin Oncol 27:843-850, 2009	3263
Tandstad T, Dahl O, Cohn-Cedermark G, et al: J Clin Oncol 27:2122-2128, 2009	3263
Balsalobre P, Díez-Martín JL, Re A, et al: J Clin Oncol 27:2192-2198, 2009	3263
Wood AC, Laudenslager M, Haglund EA, et al: J Clin Oncol 27:521s, 2009 (suppl; abstr 10008b)	3263

Also in This Issue

[Information for Subscribers](#)

[Information for Contributors](#)

[Manuscript Submission Checklist](#)

[Current Abstracts](#)

[Forthcoming Reports](#)



Online supplementary information available at www.jco.org



Diagnosis in Oncology and Correspondence available online at www.jco.org